Literature DB >> 10546479

Role of neutrophil apoptosis in the resolution of pulmonary inflammation.

K Mecklenburgh1, J Murray, T Brazil, C Ward, A G Rossi, E R Chilvers.   

Abstract

Neutrophil-mediated lung injury may result from one or more of the following possible causes: 1) loss of the normal mechanisms that regulate and switch off neutrophil influx, 2) inappropriate or uncontrolled neutrophil activation within the lung, 3) inhibition of neutrophil apoptosis, and 4) impairment or saturation of the normal macrophage-dependent process for the removal of apoptotic neutrophils. Current in vitro data indicate that many factors operating at the inflamed site (e.g. cytokines, growth factors, chemotactic peptides, hypoxia, acidosis, etc.) serve a dual function in both priming and activating these cells, and delay apoptosis. The observation that the rate of eosinophil apoptosis can be accelerated by corticosteroid therapy in vivo suggests a novel mode of action for this drug and indicates that targeting this process in other granulocyte-dependent inflammatory conditions may offer a novel therapeutic approach in inflammatory lung disease.

Entities:  

Mesh:

Year:  1999        PMID: 10546479

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  15 in total

1.  Acute lung injury: apoptosis in effector and target cells of the upper and lower airway compartment.

Authors:  B Roth Z'graggen; J Tornic; B Müller-Edenborn; L Reyes; C Booy; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  p-Synephrine suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-κB signaling pathway.

Authors:  Qianchao Wu; Ruisheng Li; Lanan Wassy Soromou; Na Chen; Xue Yuan; Guoquan Sun; Beibei Li; Haihua Feng
Journal:  Inflamm Res       Date:  2014-02-01       Impact factor: 4.575

3.  Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice.

Authors:  Zhibao Chen; Xuemei Zhang; Xiao Chu; Xiaozhe Zhang; Keji Song; Youshuai Jiang; Lu Yu; Xuming Deng
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

Review 4.  Resolvins: natural agonists for resolution of pulmonary inflammation.

Authors:  Mohib Uddin; Bruce D Levy
Journal:  Prog Lipid Res       Date:  2010-09-29       Impact factor: 16.195

5.  Chemoattractant-induced signaling via the Ras-ERK and PI3K-Akt networks, along with leukotriene C4 release, is dependent on the tyrosine kinase Lyn in IL-5- and IL-3-primed human blood eosinophils.

Authors:  Yiming Zhu; Paul J Bertics
Journal:  J Immunol       Date:  2010-11-24       Impact factor: 5.422

6.  Angiostatin inhibits acute lung injury in a mouse model.

Authors:  Gurpreet K Aulakh; Sarabjeet S Suri; Baljit Singh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

7.  Differential role of the Fas/Fas ligand apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress syndrome.

Authors:  Andrea D Lopez; Sreedevi Avasarala; Suman Grewal; Anuradha K Murali; Lucille London
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling.

Authors:  Yang Li; Gefu Chi; Bingyu Shen; Ye Tian; Haihua Feng
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

9.  Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis.

Authors:  Joanna Murray; Carol Ward; Joseph T O'Flaherty; Ian Dransfield; Christopher Haslett; Edwin R Chilvers; Adriano G Rossi
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  Sulfur dioxide attenuates LPS-induced acute lung injury via enhancing polymorphonuclear neutrophil apoptosis.

Authors:  Hui-Jie Ma; Xin-Li Huang; Yan Liu; Ya-Min Fan
Journal:  Acta Pharmacol Sin       Date:  2012-07-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.